SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Nutanix issued a press release on August 26, 2026 announcing financial results for its fourth fiscal quarter and fiscal year ended July 31, 2026, disclosing ARR growth of 16% YoY, revenue of $2.85 billion for FY26, strong free cash flow of $840.7 million, and forward guidance for Q1 FY27 and FY27. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial performance and trajectory.
View raw filing on EDGAR →Optimi Health entered into an equity line of credit (ELOC) with Seven Knots, LLC on August 13, 2026, granting the Company the right to sell up to US$100 million of common shares over the facility's term. The Company also issued convertible promissory notes (US$1.5 million initially, potentially US$500,000 more) convertible into common shares at 95% of the 20-day VWAP with a US$3.00 floor. This is a dilutive equity issuance arrangement that provides the Company with capital-raising flexibility while creating significant shareholder dilution risk, particularly given the convertible notes' favorable conversion terms and the ELOC's discretionary draw structure.
View raw filing on EDGAR →This is a press release announcing Perion's acquisition of PRN, a leading in-store retail media company, for up to $12 million in cash. The disclosure explicitly describes the transaction as an acquisition that "accelerates Perion's in-store media presence" and "scales Perion's digital suite directly into exclusive point-of-purchase environments." This is a material acquisition that expands Perion's addressable market within the $70B+ U.S. retail media market and is expected to be accretive from closing, making it material to investors' assessment of the company's strategic direction and financial performance.
View raw filing on EDGAR →The Company issued 140,000 Class B Ordinary Shares to CEO/Chairman Pengfei Jiang at par value (US$350 total), which immediately grants him approximately 64.0% of aggregate voting power through a super-voting structure (30 votes per Class B share vs. 1 vote per Class A share). While the dollar amount is nominal, the dilutive effect and control concentration are material to investors assessing governance and ownership structure. This is a related-party equity issuance that materially shifts voting control, though the primary mechanism is super-voting rather than traditional dilution.
View raw filing on EDGAR →This is a press release disclosing ParaZero's financial results for the six months ended June 30, 2026, including sales growth of 195.3% to $1,057,210, gross margin improvement from negative 20.6% to 36%, and operating/net loss figures. The document explicitly states "reported today its financial results for the six months ended June 30, 2026" and presents detailed financial highlights typical of an interim earnings release. This is material to investors as it demonstrates significant revenue acceleration and margin improvement in the company's core defense business.
View raw filing on EDGAR →The filing discloses Item 5.07 results from VSee Health's August 25, 2026 annual stockholder meeting, including voting outcomes on four proposals: election of two directors (Kevin Lowdermilk and Colin O'Sullivan), ratification of WWC, P.C. as independent auditor, approval of reverse stock split authority (1-for-20 to 1-for-80), and adjournment authority. The reverse stock split approval is particularly material as it grants the board discretionary authority to consolidate shares up to 1-for-80 within two years, which would significantly affect share structure and is a common delisting-prevention mechanism.
View raw filing on EDGAR →The disclosure centers on Amendment No. 1 to the Executive Employment Agreement with Jeffery Harris (CTO), which fixes the number of restricted stock units for the first-year annual bonus award at 49,778 units. This is a compensatory arrangement modification for a named executive officer, falling squarely within exec_compensation rather than exec_appointment or exec_departure, as the principal action is clarifying and fixing the equity grant terms of an existing employment agreement.
View raw filing on EDGAR →This exhibit is a press release announcing UP Fintech's unaudited second quarter 2026 financial results, dated August 26, 2026. The document discloses total revenues of US$182.3 million (31.4% YoY growth), net income of US$39.4 million, and key operating metrics including 1,315,400 funded accounts and US$60.7 billion in total client assets. The CEO's statement, financial highlights, and detailed results tables are characteristic of a quarterly earnings release, which is a material event affecting investor assessment of the company's financial performance and trajectory.
View raw filing on EDGAR →Western Digital entered into exchange agreements to retire approximately $191.0 million in convertible notes through a combination of cash ($192.7 million) and equity issuance (Exchange Shares). The transaction materially restructures the company's capital structure by converting debt obligations into equity.
View raw filing on EDGAR →The Board of Directors resolved to issue up to US$1.8 billion in 7th Unsecured Overseas Convertible Bonds. This is a material creation of a new direct financial obligation. Although the bonds are convertible into shares, the primary disclosure is the debt issuance itself—a significant capital-raising event that would materially affect a reasonable investor's assessment of UMC's capital structure and financial obligations.
View raw filing on EDGAR →Kohl's Corporation issued a press release on August 26, 2026, reporting quarterly earnings for the period ended August 1, 2026, with diluted EPS of $1.28 and year-to-date EPS of $1.18, along with raised full-year 2026 financial guidance (adjusted operating margin 3.5%-4.0%, adjusted diluted EPS $1.80-$2.40) and announcement of a restarted share repurchase program.
View raw filing on EDGAR →Kohl's Board declared a quarterly cash dividend of $0.125 per share on August 18, 2026, payable September 23, 2026, to shareholders of record on September 9, 2026.
View raw filing on EDGAR →Alibaba completed an HK$80 billion placing of 710 million newly issued ordinary shares to non-U.S. persons at HK$112.70 per share under Regulation S, representing approximately 3.70% dilution to existing shareholders. The net proceeds of HK$79.7 billion are earmarked for AI infrastructure investment.
View raw filing on EDGAR →This exhibit discloses the results of an Extraordinary General Meeting of shareholders held on August 24, 2026, with detailed voting tallies for five proposals. The disclosure includes approval of a material share repurchase of 5,000,000 shares from Harraden Circle Investors for US$52.45 million, general authorities for future share repurchases, and amendments to the company's articles of association. The detailed vote counts and percentages for each resolution are presented in tabular form, which is the hallmark of a shareholder vote results disclosure under Item 5.07 equivalent.
View raw filing on EDGAR →Aegon disclosed entry into a voting undertaking agreement with its largest shareholder (18.4% voting rights) on August 25, 2026, in connection with a proposed cross-border redomiciliation from Bermuda to Delaware. The shareholder has committed to vote in favor of the redomiciliation and adoption of the 2027 Omnibus Incentive Plan at an October 8, 2026 special general meeting. This is a material governance event involving a fundamental change in corporate jurisdiction and secured shareholder support, though it does not fit the specific categories of exec_appointment, exec_departure, or shareholder_vote_results (the vote has not yet occurred).
View raw filing on EDGAR →Celcuity announced submission of a supplemental New Drug Application (sNDA) to the FDA for REVTORPYK (gedatolisib) for HR+/HER2- breast cancer with PIK3CA mutations, representing a material regulatory milestone and significant step toward expanding the approved indication for the already-approved drug based on positive Phase 3 VIKTORIA-1 trial results.
View raw filing on EDGAR →Fidelity Core Real Estate Fund disclosed its financial results and performance metrics as of July 31, 2026, including NAV per share of $11.61, annualized total returns of 8.96% since inception, distribution rates of 4.74%, and portfolio composition of $669.6M gross value across 15 assets with 99% occupancy. The disclosure includes standardized performance metrics comparable to the ODCE index.
View raw filing on EDGAR →Vista Credit Strategic Lending Corp. completed an unregistered sale of 104,462.348 shares of Class I common stock for $1,995,000 to accredited investors and non-U.S. persons pursuant to subscription agreements, relying on Section 4(a)(2) and Regulation D/S exemptions.
View raw filing on EDGAR →The Company disclosed preliminary financial metrics as of July 31, 2026, including net asset value per share of $19.10, total investments of $2.2 billion, and a debt-to-equity ratio of 0.96x.
View raw filing on EDGAR →Leggett & Platt completed a merger in which shareholders received 0.1455 shares of Parent common stock per share held, with all equity awards assumed and converted by Parent. The merger resulted in a change of control, termination of material debt agreements ($277 million credit facility and commercial paper program), delisting from NYSE, and amendments to the company's articles and bylaws as the surviving entity.
View raw filing on EDGAR →Item 3.03 discloses material modifications to the rights of security holders in connection with the merger completion, incorporating by reference the M&A, delisting, change of control, and charter amendment items. The specific nature of the modification cannot be fully determined from Item 3.03 alone, but the cross-reference structure indicates governance-related changes affecting shareholder rights.
View raw filing on EDGAR →The disclosure announces FDA approval of RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma, a major regulatory and commercial milestone for Revolution Medicines. This is a material operational event—the product is now available for prescription in the United States—but does not fit the specific named categories (earnings, M&A, impairment, etc.). The approval is based on successful Phase 3 trial data (RASolute 302) and includes pricing information ($39,800 for a 30-day supply), indicating commercial readiness and materiality to investors assessing the company's pipeline and revenue prospects.
View raw filing on EDGAR →The Sponsor discloses an intention to liquidate Staking Rewards for cash to be distributed to shareholders monthly on a two-month lagged basis. This constitutes a distribution of capital to security holders, fitting the dividend_distribution category. While the language is somewhat operational in tone (describing the mechanics of staking and re-staking), the core event is the declaration of a distribution policy to shareholders, which is material to investors in this ETF.
View raw filing on EDGAR →CSB Bancorp announced its Board of Directors' declaration of a third quarter cash dividend of $0.45 per share, payable September 22, 2026. The disclosure explicitly states this represents a $0.02 increase in the linked quarterly dividend and a $0.04 increase over the prior year, signaling a material capital allocation decision that would affect investor assessment of the company's financial position and shareholder returns.
View raw filing on EDGAR →The filing discloses the issuance of 23,031,494 Series A Common Warrants with an exercise price of $6.35 per share, which if exercised in full would provide approximately $146.2 million in capital. The warrants become exercisable upon the enrollment of the 500th subject in the ELAINE-3 Trial (triggered by this 8-K announcement), making this a material dilutive issuance. While the filing also announces a clinical trial milestone, the substantive disclosure centers on the warrant exercise mechanics and potential capital raise, characteristic of dilutive equity issuances.
View raw filing on EDGAR →The Board of Trustees declared a regular distribution on the Fund's common shares of $0.1600 per share (gross) across multiple share classes, payable on September 28, 2026.
View raw filing on EDGAR →Northern Oil & Gas issued $500 million in aggregate principal amount of 7.500% Senior Notes due 2034 pursuant to an indenture dated August 26, 2026. This represents a material creation of a direct financial obligation through debt issuance with an 8-year maturity and detailed covenant structure.
View raw filing on EDGAR →The filing discloses the dismissal of CohnReznick LLP as the Company's independent registered public accounting firm effective August 21, 2026, and the simultaneous appointment of Deloitte & Touche LLP as the new auditor. This is a classic auditor change under Item 4.01, which is material to investors as it affects the registrant's financial reporting oversight and audit independence.
View raw filing on EDGAR →The filing discloses the Board of Directors' declaration of quarterly cash dividends on common shares ($0.32 per share), Series A preferred stock ($0.75 per share), and Series B-1 preferred stock ($2.12 per share), all payable October 2, 2026. This is a routine but material dividend declaration that affects shareholder returns and is typically disclosed via Item 7.01 Regulation FD Disclosure.
View raw filing on EDGAR →Michael R. Haack, age 53, was elected to Champion Homes' Board of Directors effective August 26, 2026, expanding the Board from six to seven directors and was appointed to the Compensation Committee. The appointment of an independent director with significant industrial and manufacturing leadership experience is material to investors' assessment of board composition and governance.
View raw filing on EDGAR →This is a straightforward earnings release for Synopsys' third fiscal quarter ended July 31, 2026. The Item 2.02 disclosure announces quarterly revenue of $2.477 billion, GAAP EPS of $2.84, and non-GAAP EPS of $3.91, along with raised full-year guidance. The press release is attached as Exhibit 99.1 and contains detailed financial results, segment performance, and forward-looking guidance—all hallmarks of a quarterly earnings announcement.
View raw filing on EDGAR →The Board of Directors authorized an additional $150 million share repurchase program, which constitutes a return of capital to shareholders. Share repurchases are classified as dividend distributions under the taxonomy as they represent a distribution or return of capital to holders. The authorization is material as it signals capital allocation strategy and affects shareholder value, with the CEO explicitly stating the program reflects "disciplined approach to capital allocation" and "maximize shareholder value."
View raw filing on EDGAR →The 6-K discloses results of an Extraordinary General Meeting held on August 21, 2026, where shareholders voted on two proposals: (1) approval of a Share Capital Increase from US$50,000 to US$12,500,000 (approved with 61,471 votes for, 54,414 against), and (2) adoption of amended articles of association (not approved, failing the two-thirds special resolution threshold with 66,754 for and 53,203 against). This is a direct disclosure of shareholder vote results under Item 5.07 equivalent, and the capital increase approval is material to investors as it substantially increases authorized shares from 2 million to 500 million.
View raw filing on EDGAR →Great Elm Group issued a press release on August 26, 2026, disclosing fiscal 2026 fourth quarter and full-year financial results, including total revenue of $27.8 million (70% increase), a net loss of $35.4 million (driven primarily by GECC share price decline), and key operational metrics such as fee-paying AUM of $590 million and cash of $53.5 million. This is a standard earnings release filed under Item 2.02 and furnished as Exhibit 99.1.
View raw filing on EDGAR →The filing discloses quarterly and six-month financial results for Strategic Storage Trust VI, Inc. for the periods ended June 30, 2026, presented as a press release furnished as Exhibit 99.1. The disclosure includes consolidated balance sheets, statements of operations, and same-store operating metrics—the hallmark of an earnings release. Although the Item 7.01 designation (Regulation FD Disclosure) indicates the information is furnished rather than filed, the substance is a material earnings announcement that would affect investor assessment of the registrant's financial performance and position.
View raw filing on EDGAR →AstroNova completed its acquisition by affiliates of Arcline Investment Management for $29.00 per share in an all-cash transaction totaling approximately $241.9 million. The merger resulted in a change of control, with AstroNova becoming a wholly owned subsidiary of Arcline, ceasing Nasdaq trading, and terminating its public company status and Exchange Act registration.
View raw filing on EDGAR →The disclosure announces CDN$20 million (approximately US$14 million) in government financial support to a subsidiary, consisting of a non-repayable contribution (CDN$1 million) and a repayable contribution (CDN$19 million) commencing repayment in 2031. This is a material financial event involving capital infusion and debt-like obligations, but does not fit the specific categories of debt_issuance (no direct obligation created by the company), dividend_distribution, or other named financial types. The event is clearly financial in nature and material to investors assessing the company's capital position and liquidity, making financial_other the most appropriate classification.
View raw filing on EDGAR →The filing discloses the dismissal of Grant Thornton LLP as the independent registered public accounting firm effective August 21, 2026, and the simultaneous appointment of Deloitte & Touche LLP as the new auditor for fiscal year 2027. This is a classic auditor change under Item 4.01, with no disagreements or reportable events disclosed, indicating a routine transition rather than a conflict-driven change.
View raw filing on EDGAR →Immatics announced an underwritten offering of 12,945,916 ordinary shares at $8.69 per share plus pre-funded warrants to purchase 4,315,304 ordinary shares, raising $150 million in gross proceeds. This is a registered public offering of equity securities that will dilute existing shareholders, fitting the definition of a dilutive issuance. The material size ($150M) and explicit warrant structure make this a significant capital-raising event material to investors.
View raw filing on EDGAR →Ovintiv disclosed a material update on its 2026 "ground game acquisition program," announcing over 60 transactions adding approximately 41,000 net acres and 240 well locations across Permian and Montney assets for ~$460 million. While this involves acquisitions of land and drilling inventory, the disclosure focuses on an operational/strategic capital deployment program rather than a discrete M&A transaction meeting the definition of "material acquisition" (Item 1.01). The company characterizes this as an ongoing inventory-building initiative with multiple small transactions, making it an operational capital strategy rather than a single material M&A event.
View raw filing on EDGAR →Gulf Resources announced a strategic cooperation agreement with Brazilian company Montes Verdes Participacoes Ltda. to establish a joint venture for international expansion in bromine, lithium, and other mineral extraction. The agreement includes revenue guarantees ($180M in 2027, 20% annual growth thereafter) and potential dilutive share issuance. This is a material operational and strategic business event involving a partnership and joint venture formation, but does not constitute a traditional M&A transaction (acquisition, merger, or change of control). The disclosure is material to investors as it represents a significant strategic pivot and expansion plan with financial commitments and potential equity dilution.
View raw filing on EDGAR →Somnigroup International Inc. completed its acquisition of Leggett & Platt, Incorporated on August 26, 2026, pursuant to a Merger Agreement dated April 13, 2026. The all-stock transaction was valued at approximately $2.3 billion with an exchange ratio of 0.1455 Somnigroup shares per Leggett & Platt share, creating a combined entity with 170+ facilities and 36,000+ employees with targeted synergies of $75 million.
View raw filing on EDGAR →As part of the acquisition completion, Somnigroup assumed $1.5 billion in aggregate principal amount of Leggett & Platt's outstanding senior notes (3.50% due 2027, 4.40% due 2029, and 3.50% due 2051), creating direct financial obligations for the registrant.
View raw filing on EDGAR →The 6-K discloses completion of a merger on August 26, 2026, whereby Merger Sub merged with and into MBody AI, with MBody AI surviving as a wholly-owned subsidiary of Check-Cap. MBody AI shareholders received approximately 12.4 million ordinary shares representing 90% of Check-Cap's post-closing equity, constituting a change of control under Nasdaq Listing Rule 5110(a). This is a material acquisition/change of control event requiring disclosure under Item 1.01 or 2.01 of Form 8-K equivalents.
View raw filing on EDGAR →Amendment to a Secured Convertible Promissory Note originally issued December 11, 2025 ($16,070,000 principal) modifying the conversion price formula and adding a new intraday hourly VWAP definition, materially altering the terms of the existing debt obligation.
View raw filing on EDGAR →Amendment to Pre-Paid Purchase agreement #1 originally issued July 6, 2026 ($1,080,000) modifying the share purchase price formula to 85% of the lowest VWAP over specified periods, materially altering the pricing terms for equity conversion and increasing dilution to existing shareholders.
View raw filing on EDGAR →The Company received a Notice of Acceleration from its lender (ACP Agency, LLC) following Events of Default previously disclosed on August 11, 2026. The lender has exercised remedies, terminating all commitments and accelerating approximately $18.9 million in debt obligations to be immediately due and payable. This is a classic covenant breach triggering event that materially accelerates a direct financial obligation and represents a critical financial stress indicator.
View raw filing on EDGAR →The 6-K discloses a Nasdaq notice that Primech failed to meet the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), with the stock trading below $1.00 for 30 consecutive business days. Although the Company has been granted a 180-day cure period (until February 22, 2027) and faces no immediate delisting, this is a material disclosure of delisting risk under Item 3.01 equivalent. The notice explicitly warns of potential delisting if compliance is not regained, making this a significant governance and listing-status event material to investors.
View raw filing on EDGAR →This announcement discloses a material clinical milestone: dosing the first patient in the second cohort of a Phase 1/2a trial of RV-01, the company's lead radiopharmaceutical therapeutic developed through its joint venture with MD Anderson Cancer Center. The advancement to the 70 mCi dose level following a positive Safety and Monitoring Committee recommendation represents a significant operational and clinical progression for a clinical-stage biopharmaceutical company. While not a discrete event type like M&A, exec change, or debt issuance, this clinical advancement is material to investors' assessment of the company's pipeline development and is best classified as an operational milestone.
View raw filing on EDGAR →Wetour Robotics entered into an at-the-market (ATM) sales agreement with Rodman & Renshaw LLC on August 26, 2026, to issue and sell ordinary shares from time to time. ATM offerings are unregistered equity issuances that are dilutive to existing shareholders and typically signal capital-raising activity at small- and mid-cap issuers. The agreement is registered under the company's Form F-3 shelf registration statement and permits sales on the Nasdaq Capital Market or other trading venues, with the sales agent receiving up to 3.0% commission.
View raw filing on EDGAR →